AstraZeneca shares trade higher on UBS Upgrade
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
AstraZeneca PLC (AZNCF)AstraZeneca PLC stock price live, this page displays LON AZN stock exchange data. View the AZN premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the AstraZeneca PLC real time stock price chart below.
What Is the AstraZeneca PLC Stock Price Today?
The AstraZeneca PLC stock price today is 134.600.
What Is the Stock Symbol for AstraZeneca PLC?
The stock symbol for AstraZeneca PLC is ""AZN.""
What Stock Exchange Does AstraZeneca PLC Trade On?
AstraZeneca PLC is listed and trades on the London stock exchange.
Is AstraZeneca PLC a Good Stock to Buy?
Determining whether AstraZeneca PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AZN quote. (ISIN: GB0009895292)
What Is the AstraZeneca PLC Stock Price Today?
The AstraZeneca PLC stock price today is 134.600.
What Is the Stock Symbol for AstraZeneca PLC?
The stock symbol for AstraZeneca PLC is ""AZN.""
What Stock Exchange Does AstraZeneca PLC Trade On?
AstraZeneca PLC is listed and trades on the London stock exchange.
Is AstraZeneca PLC a Good Stock to Buy?
Determining whether AstraZeneca PLC—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the AZN quote. (ISIN: GB0009895292)
OTC Markets
Currency in USD
134.600
-1.020(-0.75%)
Closed
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
132.500
137.620
52 wk Range
118.160
175.000
AZNCF Scorecard
Full Analysis
Net income is expected to grow this year
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
132.500137.620
52 wk Range
118.160175.000
Key Statistics
Edit
Book Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
Unlock(0.74%)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockBook Value / Share
UnlockFair Value
UnlockFair Value Upside
UnlockEPS Growth Forecast
Unlock(0.74%)
Dividends Payment Streak
UnlockEBITDA
UnlockEV/EBITDA
UnlockAZNCF Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceFair Price
Upside
Price Target
17,792.800
Upside
+64.901%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Trading at a high earnings multiple
- Astrazeneca receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Astrazeneca receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Astrazeneca receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Astrazeneca receives Investment Bank Analyst Rating Update
- Investing.com
Pro
- AstraZeneca shares trade higher on UBS Upgrade
- Investing.com
- Astrazeneca receives Investment Bank Analyst Rating Update
- Investing.com
Pro - Astrazeneca receives Investment Bank Analyst Rating Update
- Investing.com
Pro - AstraZeneca raises 2024 outlook on strong Q3
- Investing.com
- Astrazeneca receives Investment Bank Analyst Rating Update
- Investing.com
Pro
AstraZeneca PLC Company Profile
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
Compare AZNCF to Peers and Sector
Metrics to compare | AZNCF | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipAZNCFPeersSector | |
|---|---|---|---|---|
P/E Ratio | 31.8x | 15.4x | −0.7x | |
PEG Ratio | 3.26 | 0.21 | 0.00 | |
Price/Book | 5.1x | 2.4x | 2.6x | |
Price / LTM Sales | 4.0x | 2.0x | 3.2x | |
Upside (Analyst Target) | - | 24.6% | 46.4% | |
Fair Value Upside | Unlock | 12.0% | 6.9% | Unlock |
Dividends
Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 4.19
Dividend Yield
0.74%
Industry Median 1.74%
Annualised payout
1
Paid semi-annually
5-Years Growth
-
Growth Streak
People Also Watch
FAQ
What Is the AstraZeneca (AZNCF) Premarket Price Today?
The AstraZeneca (AZNCF) premarket price is . Premarket price change units: . Premarket percentage change: . Premarket volume: . Current date: 04 Dec 2024. Previous close: 135.62
What Stock Exchange Does AstraZeneca Trade On?
AstraZeneca is listed and trades on the OTC Markets stock exchange.
What Is the Stock Symbol for AstraZeneca?
The stock symbol for AstraZeneca is "AZNCF."
What Is the AstraZeneca (AZNCF) Afterhours Price Today? (Afterhours variable test: ) Current Date: 04 Dec 2024
After hours price: . After hours price change (units): . Price change percentage:
What Is the AstraZeneca Market Cap?
As of today, AstraZeneca market cap is 211.93B.
What is AstraZeneca Earnings Per Share?
The AstraZeneca EPS is 4.19.
What Is the Next AstraZeneca Earnings Date?
AstraZeneca will release its next earnings report on 05 Feb 2025.
From a Technical Analysis Perspective, Is AZNCF a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Buy.
What Is AstraZeneca PLC (AZNCF) Price Target According to Analysts?
Based on analysts, the average 12-month price target for AstraZeneca PLC is , with a high estimate of and a low estimate of . analysts recommend buying the stock, while suggest selling, leading to an overall rating of . The stock has an upside potential of %.
What Is AstraZeneca PLC (AZNCF) Price Target According to Analysts?
Based on analysts, the average 12-month price target for AstraZeneca PLC is , with a high estimate of and a low estimate of . analysts recommend buying the stock, while suggest selling, leading to an overall rating of . The stock has an upside potential of %.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2024 - Fusion Media Limited. All Rights Reserved.